Metabolic Supremacy Fuels Tumor Aggressiveness in Renal Cancer

Renal cell carcinoma, with clear cell renal carcinoma (ccRCC) being the dominant form, is recognized as a malignancy driven by abnormal metabolic processes, with extensive alterations in glucose, lipid, and amino acid pathways. The loss of the Von Hippel-Lindau (VHL) gene in nearly 90% of ccRCC instances results in the accumulation of hypoxia-inducible factors (HIFs), producing a pseudo-hypoxic environment that promotes metabolic supremacy. This, in return, amplifies glucose uptake and directs energy production toward aerobic glycolysis, commonly referred to as the Warburg effect, even under conditions of good oxygen supply. Simultaneously, suppression of oxidative phosphorylation and heightened activity of the pentose phosphate pathway foster biosynthetic requirements and support an immunosuppressive environment. Dysregulated lipid metabolism, including elevated fatty acid synthesis, excessive cholesterol storage, and reduced β-oxidation, also contributes to disease aggressiveness. ccRCC cells also exhibit a pronounced reliance on glutamine, powering the tricarboxylic acid (TCA) cycle and preserving redox homeostasis, whereas altered tryptophan and arginine pathways facilitate immune escape. Overall, this metabolic supremacy fuels malignant growth, promote tumor aggressiveness and metastatic spread, and foster resistance to therapy. The pursuit of interventions targeting in this regard has been promising with HIF-2α inhibitors, such as belzutifan, showing clinical benefit. Other emerging strategies focus on disrupting glycolysis, lipid biogenesis, and glutamine utilization in tackling metabolic supremacy in renal cancer. This comprehensive review delves into ccRCC’s multifaceted metabolic landscape with focus on underlying pivotal molecular pathways, their implications in tumor aggressiveness, and the potential of innovative treatments targeting metabolic supremacy to limit tumor burden and improve patient outcomes in this malignancy.